Home/Pipeline/Technosphere Platform (New Formulations)

Technosphere Platform (New Formulations)

Undisclosed

Discovery/PreclinicalActive R&D

Key Facts

Indication

Undisclosed

Phase

Discovery/Preclinical

Status

Active R&D

Company

MannKind

About MannKind

MannKind Corporation has evolved from a development-stage entity into a commercial organization with a diversified portfolio anchored by its proprietary Technosphere® inhalation platform. The company's strategy combines the commercialization of its own products—Afrezza® (inhaled insulin) and V-Go®—with strategic partnerships, as evidenced by the success of Tyvaso DPI®, and targeted acquisitions like scPharmaceuticals (FUROSCIX®). With a focus on cardiometabolic and orphan lung diseases, MannKind aims to drive growth through label expansions, pediatric studies, and leveraging its validated platform for new therapeutic applications.

View full company profile

Therapeutic Areas

Cardiometabolic Diseases Orphan Lung Diseases

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 1	Bolt Biotherapeutics	Preclinical	Available for Partnering
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active
Therapeutic Programs	Agathos Biologics	Pre-clinical	Active